Standard Operating Procedure for Cross-Functional Review of Submission Risks and Open Issues
| Department | Regulatory Affairs |
| SOP No. | RA/2026/798 |
| Supersedes | NA |
| Page No. | 1 of X |
| Issue Date | 18/04/2026 |
| Effective Date | 18/04/2026 |
| Review Date | 18/04/2028 |
Purpose
This Standard Operating Procedure (SOP) establishes a comprehensive, consistent approach for conducting cross-functional reviews of submission risks and open issues. Its objective is to ensure thorough identification, assessment, and mitigation of risks associated with regulatory submissions, facilitating timely and compliant submission processes while maintaining alignment across all relevant departments. This SOP supports regulatory and quality system controls by promoting transparency, risk awareness, and coordinated corrective actions to safeguard product approval and organizational compliance.
Scope
This SOP applies to all regulatory, quality assurance, quality control, manufacturing, clinical, and other relevant departments involved in the preparation, review, approval, and management of regulatory submissions and related documents. It covers risk identification, evaluation, documentation, and resolution tracking for all submission types including new drug applications, variations, renewals, and correspondence with regulatory authorities. Activities outside submission risk management, such as routine quality control testing or unrelated operational tasks, are excluded.
Responsibilities
The following roles are responsible for effective execution and maintenance of this SOP:
- Regulatory Affairs Specialists – Prepare submission risk assessments and coordinate reviews.
- Quality Assurance Representatives – Verify compliance and approve risk management activities.
- Cross-Functional Team Members (Manufacturing, QC, Clinical, Engineering, etc.) – Provide expert input, identify risks, and propose mitigation strategies.
- Document Control Personnel – Manage documentation, version control, and record retention.
- Supervisors and Managers – Oversee review completeness and timely closure of open issues.
- Training Coordinators – Ensure involved personnel are trained on this SOP.
Accountability
The Regulatory Affairs Head is accountable for ensuring this SOP’s effective implementation, compliance monitoring, regular review, escalation of significant risks or unresolved issues, and validation of periodic effectiveness. They are responsible for ensuring cross-functional collaboration and maintaining documentation per applicable regulations and company policies.
Procedure
1. Preparation and Prerequisites:
Before initiating the cross-functional review, the Regulatory Affairs team shall compile relevant submission dossiers, prior risk assessments, previous submission feedback, and any open compliance issues. All participants must have adequate training in risk management and this SOP.
2. Review Meeting Scheduling:
The Regulatory Affairs coordinator schedules a cross-functional review meeting inviting representatives from regulatory, QA, QC, manufacturing, clinical, and other impacted departments. Sufficient notice (minimum 5 working days) must be given and agenda distributed.
3. Risk Identification and Documentation:
During the meeting, potential submission risks (e.g., data gaps, compliance deviations, process variances) and unresolved issues are discussed. Each risk is clearly described, categorized (e.g., critical, major, minor), and documented using the Submission Risk and Issue Log (Annexure-1).
4. Risk Evaluation and Impact Assessment:
Cross-functional team evaluates the likelihood and impact of each risk on submission success, patient safety, regulatory compliance, and business continuity. Risk scoring and prioritization are performed according to company risk assessment criteria.
5. Mitigation and Action Planning:
For each identified risk or open issue, the team develops mitigation actions with clear responsibilities, timelines, and verification steps. These action plans are recorded in the Submission Risk and Issue Log.
6. Review and Approval:
Post meeting, the documented risks and mitigation plans are reviewed and approved by Quality Assurance and Regulatory Affairs management. Required changes or escalations are addressed promptly.
7. Implementation and Monitoring:
Assigned departments execute mitigation actions and monitor the progress. Status updates and new findings are periodically communicated during subsequent meetings or reports, ensuring dynamic risk management.
8. Documentation and Record Retention:
All meeting minutes, risk logs, correspondence, and supporting documents must be securely stored and controlled per document management policies. Records retention shall comply with applicable regulatory and internal requirements.
9. Management Review and Continuous Improvement:
At scheduled intervals, the Regulatory Affairs Head reviews the overall effectiveness of the risk review process, adjusting procedures or training as necessary to enhance robustness and compliance.
10. Deviations and Escalations:
Any deviation from this SOP or significant unresolved risks must be escalated immediately to senior management and documented along with corrective and preventive actions (CAPA).
Abbreviations
CAPA: Corrective and Preventive Actions
QA: Quality Assurance
QC: Quality Control
SOP: Standard Operating Procedure
RA: Regulatory Affairs
GMP: Good Manufacturing Practices
Documents
- Submission Risk and Issue Log (Annexure-1)
- Cross-Functional Review Meeting Minutes Template (Annexure-2)
- Mitigation Action Plan Form (Annexure-3)
References
ICH Q9 Quality Risk Management;
FDA Guidance for Industry: Quality Systems Approach to Pharmaceutical CGMP Regulations;
EMA Guideline on the Quality of Regulatory Submissions;
Company Quality Manual and Risk Management Procedures;
Applicable GMP and Regulatory Compliance Standards.
Version
1.0
Approval
| Prepared By | |
| Checked By | |
| Approved By |
Annexures
Annexure-1: Submission Risk and Issue Log
Purpose: To systematically document all identified submission risks and open issues including descriptions, categories, impact assessments, and assigned mitigation actions.
| Risk / Issue ID | Description | Category | Impact Level | Likelihood | Risk Score | Assigned To | Mitigation Action | Due Date | Status |
|---|---|---|---|---|---|---|---|---|---|
| SR001 | Incomplete clinical data in module 5 | Critical | High | Medium | High | Clinical Department | Complete data submission with updated reports | 30/05/2026 | Open |
| SR002 | Deviation reported in manufacturing batch records | Major | Medium | Low | Medium | Manufacturing QA | Investigate deviation and provide justification | 15/05/2026 | In Progress |
| SR003 | Pending regulatory questions from previous submissions | Major | High | High | High | Regulatory Affairs | Prepare responses and appendix documents | 20/04/2026 | Closed |
Annexure-2: Cross-Functional Review Meeting Minutes Template
Purpose: To record discussions, decisions, and action items during cross-functional review meetings focused on submission risks and open issues.
| Date: | 10/04/2026 |
| Meeting Chairperson: | Regulatory Affairs Manager |
| Participants: | Regulatory Affairs, QA, QC, Clinical, Manufacturing, Engineering |
| Agenda: | Review submission risks, evaluate mitigation status, assign actions |
Discussion Summary:
- Reviewed SR001 – clinical data gap requires expedited completion.
- SR002 deviation ongoing investigation, expected report timeline agreed.
- SR003 closed after regulatory approval received.
Action Items:
- Clinical Department to finalize data by 30/05/2026.
- Manufacturing QA to complete deviation investigation by 15/05/2026.
- Regulatory Affairs to update risk log and file records accordingly.
Next Meeting Date: 24/04/2026
Annexure-3: Mitigation Action Plan Form
Purpose: To formally plan, assign, and track actions to mitigate identified submission risks or resolve open issues.
| Action Plan ID: | MAP-001 |
| Related Risk / Issue ID: | SR001 |
| Action Description: | Complete outstanding clinical data and upload updated reports |
| Responsible Department: | Clinical Department |
| Assigned To: | Clinical Data Manager |
| Start Date: | 11/04/2026 |
| Target Completion Date: | 30/05/2026 |
| Status: | In Progress |
| Verification Method: | Review of updated submission dossier |
| Comments: | Data reconciliation underway |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
| 18/04/2026 | 1.0 | Initial issue | New SOP creation |